TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20041945
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide (200-800 mg/day) infused over 10, 15, and 30 min for 2-5 days
Study: 20042642
Drug: Glycerol solution
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycerol solution (0.57 g/mL) ingested at 3 mL/kg body weight (maximum, 250 mL)
Study: 20045791
Drug: Pegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6 mg subcutaneous dose on day 9)
Study: 20046132
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation therapy
Study: 20048179
Drug: HAI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI of FUDR (0.2 mg/m²/d) and dexamethasone, alternating with systemic therapy of oxaliplatin (130 mg/m²) and capecitabine (1,000 mg/m² twice daily)
Study: 20048179
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy of oxaliplatin (130 mg/m²) and capecitabine (1,000 mg/m² twice daily)
Study: 20048179
Drug: HAI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI of FUDR and systemic therapy
Study: 20048179
Drug: Protocol-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-directed therapy
Study: 20051022
Drug: 1-year outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-year outpatient intervention based on exercise, behavior, and nutrition therapy
Study: 20051130
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and SRT (COMB)
Study: 20061136
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (cediranib and gefitinib)
Study: 20061136
Drug: Pharmacokinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics of cediranib
Study: 20061136
Drug: Pharmacokinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics of gefitinib
Study: 20064072
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg vicriviroc
Study: 20064072
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg vicriviroc
Study: 20064208
Drug: High Intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Intensity Interval Training (HIT) performed three times weekly by Group A participants.
Study: 20064208
Drug: Moderate-vigorous physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-vigorous physical activity performed three times weekly by Group B participants.
Study: 20065126
Drug: Pramipexole with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole with levodopa infusion
Study: 20065758
Drug: Subcutaneous adiposity
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adiposity (141 patients)
Study: 20067838
Drug: Plerixafor (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (single agent, subcutaneous)
Study: 20071660
Drug: Infusions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions of donor-derived, ex vivo-expanded CD8(+) cytotoxic T lymphocyte (CTL) clones specific for tissue-restricted recipient mHAgs
Study: 30118633
Drug: Challenge dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Challenge dose of monovalent HBV vaccine
Study: 20080236
Drug: Pitavastatin 4mg
Normalized name: PITAVASTATIN 4MG TAB
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin 4mg once daily
Study: 20081096
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of electronic nose and FENO
Study: 20082929
Drug: JUPITER-eligible individuals
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: JUPITER-eligible individuals (hs-CRP > or = 2.0 mg/l, LDL-C <130 mg/dl)
Study: 20087581
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with platinum/taxane-based regimen
Study: 20088934
Drug: Dalteparin at
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin at a prophylactic dose
Study: 20093349
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg orally, twice daily plus intravenous methylprednisolone (1 to 3 g) followed by oral prednisone (1 mg/kg per day)
Study: 20095074
Drug: HAART initiated
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART initiated at CD4 cell counts 351-450 cells/ml
Study: 20095074
Drug: CD4 cell
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 cell counts less than 200 cells/ml
Study: 20095074
Drug: CD4 cell
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 cell counts 400-600 cells/ml
Study: 20095074
Drug: CD4 cell
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 cell counts greater than 600 cells/ml
Study: 20098694
Drug: Ixabepilone (BMS-247550)
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone (BMS-247550) at a dose of 20 mg/m(2) on days 1, 8, and 15 during each 28-day cycle
Study: 20101893
Drug: Baseline measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline measurements (before treatment)
Study: 20106720
Drug: Neoadjuvant capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant capecitabine and oxaliplatin (oxaliplatin 130 mg/m2 on day 1 with capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks) followed by chemoradiotherapy (54 Gy over 6 weeks) with capecitabine (825 mg/m2 twice daily) and total mesorectal excision.
Study: 20107214
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of live, oral rotavirus vaccine
Study: 20107214
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of live, oral rotavirus vaccine
Study: 20107229
Drug: Attainment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attainment of T-cell receptor rearrangement excision circle (TREC) levels of 2000 or more copies/mug DNA
Study: 20110053
Drug: Nilotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib 200 mg (single oral dose)
Study: 20111582
Drug: ADVAX (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAX (0.2 mg)
Study: 20111582
Drug: ADVAX (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAX (1.0 mg)
Study: 20111582
Drug: ADVAX (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAX (4.0 mg)
Study: 20112079
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin 600 mg administered 90 min prior to induction of anesthesia, then every eight hours for a total of four doses
Study: 20112381
Drug: Tocilizumab 2
Normalized name: tocilizumab 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 2 mg/kg
Study: 20119473
Drug: Point of
Normalized name: Precision Point of Care Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point of care (POC) urine drug testing
Study: 20124511
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (50 mg/kg/d on days 3 and 4 after transplantation)
Study: 20127732
Drug: High-dose silybin-phytosome
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose silybin-phytosome (13 g daily for 14-31 days, mean 20 days)
Study: 20133465
Drug: Estrogen administration
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen administration after GnRH antagonist and graded doses of GnRH
Study: 20133895
Drug: Dacetuzumab (SGN-40),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacetuzumab (SGN-40), 4 mg/kg and 12 mg/kg/week
Study: 20133895
Drug: Dacetuzumab (SGN-40),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacetuzumab (SGN-40), 12 mg/kg/week
Study: 20133895
Drug: Dacetuzumab (SGN-40)
Normalized name: dalotuzumab
DrugBank: Dacetuzumab (DB12589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacetuzumab (SGN-40) with steroid pre-medication
Study: 20139774
Drug: 150 mg/m
Normalized name: urea 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m cyclophosphamide
Study: 20139774
Drug: 250 mg/m
Normalized name: urea 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/m cyclophosphamide
Study: 20139774
Drug: 350 mg/m
Normalized name: urea 350 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg/m cyclophosphamide
Study: 20139774
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (150 and 250 mg/m)
Study: 20142724
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg plus gefitinib 250 mg
Study: 20147717
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy (42.5 Gy in 16 fractions over 22 days)
Study: 20147717
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation therapy (50.0 Gy in 25 fractions over 35 days)
Study: 20149262
Drug: Maintenance Sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Sorafenib (400 mg, p.o., twice a day for 12 months)
Study: 20149262
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of 3DCRT/IMRT and TACE
Study: 20149736
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously monthly (every 28 days), with loading doses on days 8 and 15 of month 1.
Study: 20150297
Drug: Former intensive
Normalized name: Triple Wormer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Former intensive insulin treatment
Study: 20150297
Drug: Former conventional
Normalized name: Triple Wormer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Former conventional insulin treatment
Study: 20151726
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV esomeprazole (80 mg infusion over 30 min, then 8 mg/hour for 71.5 hours)
Study: 20151726
Drug: No-IV esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-IV esomeprazole treatment
Study: 20151726
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV esomeprazole
Study: 20152220
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) with Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Study: 20152220
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) with Angiotensin Receptor Blockers (ARBs)
Study: 20152220
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) with ACEI or ARB
Study: 20153880
Drug: Prophylactic Low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic Low Molecular Weight Heparin (LMWH)
Study: 20153880
Drug: Adjusted-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose of LMWH through pregnancy and postpartum
Study: 20156608
Drug: Postoperative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative management (medical therapy)
Study: 20157136
Drug: Anticoagulants (90.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (90.5% of patients received anticoagulants)
Study: 20157136
Drug: No anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulants (control group not explicitly mentioned)
Study: 20160046
Drug: Famciclovir (individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir (individualized single doses based on body weight ranging from 25 to 175 mg)
Study: 20163987
Drug: MTD gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTD gemcitabine (1000 mg/m² on days 1 and 8), metronomic capecitabine (500 mg/m² twice a day on days 1-14), and sorafenib (400 mg twice a day on days 1-21) for six cycles followed by sorafenib monotherapy if clinical benefit was maintained.
Study: 20163987
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events related to the treatment regimen.
Study: 20174766
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow (BM)-derived mononuclear cells administered to patients with limb ischaemia
Study: 20174766
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell therapy for ischaemic peripheral disease
Study: 20178624
Drug: Patient-centered quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered quality improvement interventions (communication skills training and care management focused on explanatory models, socio-cultural barriers, and treatment preferences)
Study: 20180805
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg single dose followed by continuous 5 mg twice-daily dosing
Study: 20180805
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg twice-daily
Study: 20181282
Drug: Latanoprost once
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost once daily (evening)
Study: 20184783
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg once daily for 6 weeks
Study: 20184807
Drug: Antipsychotic-naive first-episode
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antipsychotic-naive first-episode schizophrenia patients
Study: 20187924
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 to 60 mg; mean dose = 45.8 mg/day; SD = 15.1) for 52 weeks
Study: 20188202
Drug: NK cell-enriched
Normalized name: IL15-NK Cell
DrugBank: IL15-NK Cell (DB15725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cell-enriched donor lymphocyte infusions (DLIs)
Study: 20189159
Drug: 1% mecamylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% mecamylamine topically twice daily for 12 weeks
Study: 20190585
Drug: Enhanced vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced vaccine education intervention with pictures and application vignettes and enhanced risk-reduction counseling (3 one-on-one counseling sessions)
Study: 20191499
Drug: DHEA substitution
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA substitution (50 mg/day)
Study: 20194866
Drug: Ofatumumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (300 mg for dose 1; 2000 mg for doses 2 to 12) administered as eight weekly infusions followed by four monthly infusions over 24 weeks
Study: 20200024
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg daily on 4-week cycles
Study: 20203173
Drug: Sunitinib (SU)
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib (SU) 37.5 mg daily
Study: 20205741
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi exercise (twice weekly for 12 weeks)
Study: 20205864
Drug: Weekly short-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly short-time recalls for EBF at week 6
Study: 20205864
Drug: Weekly short-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly short-time recalls for PBF at week 6
Study: 20205864
Drug: Weekly short-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly short-time recalls for EBF at week 12
Study: 20205864
Drug: Weekly short-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly short-time recalls for PBF at week 12
Study: 20206940
Drug: Intravenous ECG
Normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ECG monitoring during PICC insertion
Study: 20210645
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV) prime at week 0 followed by a 23-valent pneumococcal polysaccharide vaccine (PPV) boost at week 4
Study: 20211302
Drug: Any beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any beta-blocker for patients with LVSD
Study: 20211302
Drug: Evidence-based beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based beta-blocker for patients with LVSD
Study: 20211302
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for patients with atrial fibrillation
Study: 20211302
Drug: Aldosterone antagonist
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone antagonist for patients with LVSD
Study: 20211560
Drug: Oral masitinib
Normalized name: axitinib Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral masitinib at 7.5mg/kg/d
Study: 20214798
Drug: Additional parenteral
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional parenteral nutrition (APN)
Study: 20216101
Drug: Food allergy
Normalized name: Nutritional Supplement Oral Powder for Suspension [FOOD ALLERGY FORMULA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food allergy screening (skin prick, atopy patch, serum-specific IgE, IgG, IgG4 testing)
Study: 20216101
Drug: Skin prick,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin prick, atopy patch, and serum-specific testing
Study: 20220062
Drug: Dynamic contrast-enhanced
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before treatment (day 0) and on day 7 after induction chemotherapy
Study: 20221623
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with verteporfin alone (PDT)
Study: 20221623
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy combined with intravitreal bevacizumab (COMB)
Study: 20222977
Drug: Canfosfamide plus
Normalized name: Canfosfamide
DrugBank: Canfosfamide (DB04972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canfosfamide plus pegylated liposomal doxorubicin (PLD) at 960/50 mg/m2
Study: 20225992
Drug: Monthly intravenous
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intravenous C.E.R.A.
Study: 20226028
Drug: Heavy ion
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy ion therapy (HIT) with a target dose of 60-66 Gy E, including 45 Gy PT and a carbon ion boost of 15-21 Gy E, administered weekly in fractions of 5-6 x 3 Gy E
Study: 20230209
Drug: IV esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV esomeprazole 40 mg twice daily for 48 hours (can continue for another 24 hours if no prepyloric enteral feedings planned)
Study: 20230418
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment of acute pulmonary embolism with low NT-proBNP levels (< 500 pg mL(-1)).
Study: 20231206
Drug: No immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunosuppressive therapy
Study: 20233136
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow cells (BMSC)
Study: 20234331
Drug: PCV-7 vaccine
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCV-7 vaccine administered at 2, 4, and 6 months after birth
Study: 20234331
Drug: PCV-7 vaccine
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCV-7 vaccine administered
Study: 20236340
Drug: Menstrual migraine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menstrual migraine treatment episodes
Study: 20236340
Drug: Nonmenstrual migraine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmenstrual migraine treatment episodes
Study: 20236700
Drug: AHU377 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHU377 200 mg
Study: 20237066
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K concentration in subcutaneous adipose tissue
Study: 20298563
Drug: Patient activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient activation intervention (letter to discuss thiazide diuretics)
Study: 20299511
Drug: Velaglucerase alfa
Normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Velaglucerase alfa (60 U/kg per infusion) during phase 1/2
Study: 20299511
Drug: Velaglucerase alfa
Normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Velaglucerase alfa (30 U/kg per infusion) during extension study
Study: 20307284
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega 3 fatty acid supplement (exact dosage not specified)
Study: 20307398
Drug: Controlled-release alpha
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release alpha lipoic acid (CRLA) 600 mg twice daily for 16 weeks